Argus Raises Sanofi (SNY) Price Target to $50.00
Sanofi (NYSE:SNY) had its price target hoisted by stock analysts at Argus from $48.00 to $50.00 in a report released on Thursday. The firm presently has a “buy” rating on the stock. Argus’ price objective would indicate a potential upside of 9.67% from the stock’s previous close.
Several other brokerages also recently weighed in on SNY. Barclays raised shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Thursday, November 1st. ValuEngine raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Wednesday, October 17th. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “sell” rating in a research note on Tuesday, October 16th. Wolfe Research assumed coverage on shares of Sanofi in a research note on Tuesday, October 23rd. They issued a “market perform” rating for the company. Finally, Guggenheim assumed coverage on shares of Sanofi in a research note on Monday, October 8th. They issued a “neutral” rating for the company. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. Sanofi currently has a consensus rating of “Hold” and an average price target of $49.50.
NYSE:SNY opened at $45.59 on Thursday. Sanofi has a 52-week low of $37.43 and a 52-week high of $46.25. The firm has a market cap of $113.69 billion, a PE ratio of 14.08, a PEG ratio of 2.57 and a beta of 0.70. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85.
In other news, major shareholder Sanofi sold 104,552 shares of the company’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $406.68, for a total transaction of $42,519,207.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.00% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Dean Capital Investments Management LLC acquired a new position in shares of Sanofi during the 3rd quarter valued at about $226,000. Loeb Partners Corp increased its stake in shares of Sanofi by 15.9% during the 3rd quarter. Loeb Partners Corp now owns 10,945 shares of the company’s stock valued at $489,000 after acquiring an additional 1,500 shares during the last quarter. FMR LLC increased its stake in shares of Sanofi by 7.5% during the 3rd quarter. FMR LLC now owns 8,527,983 shares of the company’s stock valued at $380,945,000 after acquiring an additional 595,125 shares during the last quarter. Girard Partners LTD. acquired a new position in shares of Sanofi during the 3rd quarter valued at about $154,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Sanofi by 15,317.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 156,183 shares of the company’s stock valued at $6,976,000 after acquiring an additional 155,170 shares during the last quarter. 7.53% of the stock is owned by institutional investors.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Article: Day Trading
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.